EP3011013A4 - Verfahren zur behandlung von ovarialkrebs - Google Patents

Verfahren zur behandlung von ovarialkrebs Download PDF

Info

Publication number
EP3011013A4
EP3011013A4 EP14813679.9A EP14813679A EP3011013A4 EP 3011013 A4 EP3011013 A4 EP 3011013A4 EP 14813679 A EP14813679 A EP 14813679A EP 3011013 A4 EP3011013 A4 EP 3011013A4
Authority
EP
European Patent Office
Prior art keywords
treatment
methods
ovarian cancer
ovarian
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14813679.9A
Other languages
English (en)
French (fr)
Other versions
EP3011013A2 (de
Inventor
Charles Schweizer
Daniel John O'SHANNESSY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of EP3011013A2 publication Critical patent/EP3011013A2/de
Publication of EP3011013A4 publication Critical patent/EP3011013A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP14813679.9A 2013-06-20 2014-06-20 Verfahren zur behandlung von ovarialkrebs Withdrawn EP3011013A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361837543P 2013-06-20 2013-06-20
PCT/US2014/043402 WO2014205342A2 (en) 2013-06-20 2014-06-20 Methods for treatment of ovarian cancer

Publications (2)

Publication Number Publication Date
EP3011013A2 EP3011013A2 (de) 2016-04-27
EP3011013A4 true EP3011013A4 (de) 2017-03-15

Family

ID=52105530

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14813679.9A Withdrawn EP3011013A4 (de) 2013-06-20 2014-06-20 Verfahren zur behandlung von ovarialkrebs

Country Status (8)

Country Link
US (2) US20160311921A1 (de)
EP (1) EP3011013A4 (de)
JP (1) JP6383787B2 (de)
AU (1) AU2014284212B2 (de)
BR (1) BR112015031950A2 (de)
CA (1) CA2914237A1 (de)
MX (1) MX2015017950A (de)
WO (1) WO2014205342A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (de) * 2005-04-22 2010-04-07 Morphotek Inc. Antikörper mit Immuneffektoraktivität, die in Folatrezeptor alpha-positive Zellen internalisiert werden
CN122075735A (zh) * 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
MA50102A (fr) 2017-11-14 2020-07-15 Univ Virginia Patent Foundation Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
EP3765521A4 (de) 2018-03-13 2022-03-23 Phanes Therapeutics, Inc. Anti-folat-rezeptor-1-antikörper und verwendungen davon
CA3164797A1 (en) * 2019-12-23 2021-07-01 Eisai R&D Management Co., Ltd. Method of producing eribulin based antibody-drug conjugate
EP4166569A1 (de) * 2021-10-18 2023-04-19 Fondazione IRCCS Istituto Nazionale dei Tumori Gegen alpha-folat-rezeptor gerichtete antikörper
CN117741149A (zh) * 2024-02-19 2024-03-22 卡秋(江苏)生物科技有限公司 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
US6351666B1 (en) 1998-02-27 2002-02-26 Biofield Corp. Method and apparatus for sensing and processing biopotentials
JP3952599B2 (ja) 1998-07-16 2007-08-01 松下電器産業株式会社 映像表示装置および映像表示方法
WO2000004711A1 (en) 1998-07-16 2000-01-27 Imageid Ltd. Image identification and delivery system
US6694090B1 (en) 1998-07-20 2004-02-17 Thomson Licensing S.A. Method and apparatus for dynamically overriding a ratings limit during playback of a digital program
JP4322426B2 (ja) 1998-07-21 2009-09-02 エヌエックスピー ビー ヴィ データキャリヤから得たデータを少なくとも１つの他の補助キャリヤ信号によってステーションに送信するシステム
IT1303624B1 (it) 1998-07-22 2000-11-15 Techint Spa Dispositivo per elettrodeposizione a cella circonferenziale a flussidifferenziati.
DE19833226C1 (de) 1998-07-23 2000-04-20 Steuler Industriewerke Gmbh Niederschlagsrohrbündel für Naßelektrofilter
CN1089646C (zh) 1998-07-24 2002-08-28 株式会社吉野工业所 带手动泵的容器
WO2000004998A1 (en) 1998-07-24 2000-02-03 The Procter & Gamble Company Inner bag-type package having pump dispenser with improved dip tube
WO2000005435A2 (en) 1998-07-24 2000-02-03 Ce Resources Pte Ltd. Array electrophoretic apparatus
DE19833340A1 (de) 1998-07-24 2000-02-10 Karlsruhe Forschzent Wurmförmiger Arbeitsmechanismus
IT1301872B1 (it) 1998-07-24 2000-07-07 Abb Adda S P A Dispositivo di comando e controllo di interruttori di alta e mediatensione
EP1501522A4 (de) * 2002-05-06 2007-12-05 Univ Utah Res Found Vorblockierung mit nicht-ha gags erhöht die wirksamkeit von ha-konjugierten krebsmitteln
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2172487A1 (de) 2005-04-22 2010-04-07 Morphotek Inc. Antikörper mit Immuneffektoraktivität, die in Folatrezeptor alpha-positive Zellen internalisiert werden
US8465929B2 (en) * 2005-06-24 2013-06-18 Vermillion, Inc. Biomarkers for ovarian cancer
US8986650B2 (en) * 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
KR20090094148A (ko) * 2006-12-20 2009-09-03 제이-씨 헬쓰 케어 리미티드 페길화 리포좀 독소루비신의 투여 방법
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
SG189957A1 (en) * 2010-11-05 2013-06-28 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
CN107011439B (zh) 2011-07-15 2020-11-10 卫材R&D管理有限公司 抗叶酸受体α抗体及其应用
SG11201500938XA (en) * 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ARMSTRONG DEBORAH K ET AL: "Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.", GYNECOLOGIC ONCOLOGY, vol. 129, no. 3, June 2013 (2013-06-01), pages 452 - 458, XP002766348, ISSN: 1095-6859 *
DESPIERRE E ET AL: "Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.", GYNECOLOGIC ONCOLOGY, vol. 130, no. 1, July 2013 (2013-07-01), pages 192 - 199, XP002766352, ISSN: 1095-6859 *
G J RUSTIN: "Use of CA-125 to assess response to new agents in ovarian cancer trials", J CLIN ONCOL, vol. 21, no. supp 10, 1 May 2003 (2003-05-01), pages 187s - 193s, XP055446050 *
JAMES BRADFORD KLINE: "Tumor antigen CD125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-gamma receptor engagement", ONCOTARGET, vol. 8, no. 32, 7 July 2017 (2017-07-07), pages 52045 - 52060 *
KUROSAKI AKIRA ET AL: "Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.", INTERNATIONAL JOURNAL OF CANCER, vol. 138, no. 8, 15 April 2016 (2016-04-15), pages 1994 - 2002, XP002766351, ISSN: 1097-0215 *
LEUNG FELIX ET AL: "Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.", CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION : A PUBLICATION OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, COSPONSORED BY THE AMERICAN SOCIETY OF PREVENTIVE ONCOLOGY, vol. 25, no. 9, September 2016 (2016-09-01), pages 1333 - 1340, XP002766350, ISSN: 1538-7755 *
O'SHANNESSY DANIEL J ET AL: "Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.", JOURNAL OF OVARIAN RESEARCH, vol. 6, no. 1, 29, 17 April 2013 (2013-04-17), XP002766349, ISSN: 1757-2215, DOI: 10.1186/1757-2215-6-29 *
See also references of WO2014205342A2 *

Also Published As

Publication number Publication date
WO2014205342A3 (en) 2015-04-23
WO2014205342A4 (en) 2015-06-04
JP6383787B2 (ja) 2018-08-29
AU2014284212A1 (en) 2015-12-17
US20190202930A1 (en) 2019-07-04
JP2016529484A (ja) 2016-09-23
US20160311921A1 (en) 2016-10-27
CA2914237A1 (en) 2014-12-24
BR112015031950A2 (pt) 2017-07-25
EP3011013A2 (de) 2016-04-27
WO2014205342A2 (en) 2014-12-24
MX2015017950A (es) 2016-05-10
AU2014284212B2 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
IL272905A (en) Methods of treating pancreatic cancer
EP2964028A4 (de) Verbindungen zur behandlung von krebs
EP2968348A4 (de) Verbindungen zur behandlung von krebs
EP3079707A4 (de) Immuntherapie für krebs
EP3057594A4 (de) Verfahren zur behandlung von karzinomen
EP2968254A4 (de) Verfahren zur behandlung von lungenkrebs
EP3008212A4 (de) Verfahren zur behandlung von krebs
SG11201508878WA (en) Methods of treating cancer
EP2970419B8 (de) Verfahren zur behandlung von kolorektalkrebs
IL240688A0 (en) Pancreatic cancer treatment methods
EP3123173A4 (de) Verfahren zur unterdrückung von krebs durch tmcc3-hemmung
IL242546A0 (en) New compounds for cancer treatment
EP3057593A4 (de) Behandlung von bauchspeicheldrüsenkrebs
HUE048625T2 (hu) Módszer rák kezelésére
ZA201507762B (en) Methods of treating cancer
EP3074040A4 (de) Verfahren zur behandlung von karzinomen
EP2991650A4 (de) Verfahren zur behandlung von krebs
GB201607581D0 (en) Treatment of cancer
EP3076989A4 (de) Galectin-3 zur behandlung des ovarialkarzinoms
EP3049078A4 (de) Krebsbehandlung
EP3022303A4 (de) Verfahren zur behandlung von urothelialen karzinomen
EP3016948B8 (de) 2-acylaminothiazole zur behandlung von krebs
EP3007712A4 (de) Krebsbehandlung
EP3013332A4 (de) Krebsbehandlung
AU2013904620A0 (en) Method of treating cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160118

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/07 20100101AFI20170131BHEP

Ipc: G01N 33/574 20060101ALI20170131BHEP

Ipc: C12N 5/16 20060101ALI20170131BHEP

Ipc: C07K 16/28 20060101ALI20170131BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170213

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20170206BHEP

Ipc: C12N 5/16 20060101ALI20170206BHEP

Ipc: G01N 33/574 20060101ALI20170206BHEP

Ipc: C12N 5/07 20100101AFI20170206BHEP

17Q First examination report despatched

Effective date: 20180206

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EISAI INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20191217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603